Frontlight ResearchEarly access
Active, not recruitingPhase 2
A study to test if SRSD107 prevents venous thromboembolism events and how safe it is
Key facts
- Who runs it
- Sirius Therapeutics Inc.
- Where
- Bulgaria, Czechia, Hungary, Latvia, Lithuania, and Poland39 sites in 6 countriesChoose a country to see its sites
- Trial code
- Status
- Active, not recruiting
- Phase
- Phase 2
- People taking part
- 300 people, planned
- Started
- 7 Aug 2025
- Expected to end
- 7 Dec 2026
- Type of study
- Interventional
- Record updated
- 28 August 2026
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 18 criteriaShow less
Who can take part
- Able to provide written informed consent before any study assessment is performed
- Male and female subjects, of any race, between 60 and 80 years of age, inclusive. Female subjects should not be of child-bearing potential.An interim analysis of safety data will be conducted by the SSC after 50 subjects complete 12 weeks of follow-up; pending SSC approval following this analysis, enrollment of subjects between 81 and 85 years of age (inclusive) will be allowed
- Body mass index between 18.0 and 38.0 kg/m2, inclusive
- Eligible to undergo elective primary unilateral TKA under general anesthesia
- Willing to comply with study requirements including taking study drug at least 28 days prior to TKA, clinic visits, and venography at 10-14 days post TKA
- Activated partial thromboplastin time (aPTT), prothrombin time (PT), and international normalized ratio (INR) within the normal reference range at screening
- Males will agree to use contraception
Who cannot take part
- Active bleeding requiring medical or surgical intervention within 4 weeks prior to screening
- Myocardial infarction, stroke (hemorrhagic, ischemic or mixed), transient ischemic attack, systemic embolism, valvular thrombosis, or splanchnic thrombosis in the 6 months prior to screening, or any lifetime history of DVT or PE
- Positive test for human immunodeficiency virus (HIV) (CD4+>200/mm3 can be included), positive hepatitis B surface antigen, and/or active hepatitis C (by HCV RNA testing) at screening
- Known bleeding disorder, history of increased bleeding tendency (e.g., history of bleeding diathesis, known active gastrointestinal lesions such as angiodysplasia or an endoscopically verified gastrointestinal ulcer or a history of gastrointestinal bleeding within the past year) or any other condition that in the opinion of the investigator contraindicates prophylactic anticoagulation
- History of intracranial, intraspinal, or intraocular bleeding
- Evidence of active cancer, or a history of malignancy, within 2 years prior to screening. Nonmelanoma skin cancer, curatively treated localized breast or prostate cancer, or other carcinoma in situ are not exclusionary, providing that they did not require systemic chemotherapy (hormonal therapy allowed) and are considered cured
- Platelet count < 100,000/m3 at screening or a history of heparin-induced thrombocytopenia
- Estimated (by Modification of Diet in Renal Disease [MDRD]) glomerular filtration rate (eGFR) < 45 mL/min/1.73m2
- Liver dysfunction (alanine aminotransaminase or aspartate aminotransferase >1.5× upper limit of normal [ULN] or total bilirubin > ULN), liver cirrhosis (Child-Pugh class B and C excluded; Child-Pugh A allowed), history of hepatic encephalopathy, esophageal varices, or portocaval shunt. Subjects with Gilbert’s syndrome are allowed to participate
- Clinically significant anemia (hemoglobin <10 g/dL) at screening
- Uncontrolled blood pressure as defined by a systolic blood pressure ≥ 180 mmHg and/or a diastolic blood pressure ≥ 110 mmHg at the time of screening
This trial has no sites in United States.
It has sites in 6 countries. Choose a country to see its sites.
About the trial
What the trial wants to find out
To evaluate the efficacy of SRSD107 in subjects undergoing elective, primary, unilateral total knee arthroplasty (TKA) comparing SRSD107 to enoxaparin
Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.
Data and sources
- Registry record
- Listed on the EU's official list of trials (CTIS).How to verify a trial in the registry
- Official title
- A Multicenter, Randomized, Open-Label, Blinded Endpoint Evaluation, Active-Controlled Study to Compare the Efficacy and Safety of SRSD107 and Enoxaparin in Adult Subjects Undergoing Elective Primary Unilateral Total Knee Arthroplasty.
- Record updated
- 28 August 2026